辛伐他汀对尿毒症患者微炎症状态的影响

Therapeutic effect of simvastatin on microinflammation state in patients with uremia

目的观察辛伐他汀治疗对尿毒症患者血脂和炎症反应标记物的影响及差异,探讨他汀类药物在治疗尿毒症患者微炎症状态中的作用。方法选择哈尔滨医科大学附属一院肾内科尿毒症非透析患者64例,入院后测定甘油三酯(TG)、总胆固醇(TC)、白细胞介素-6(IL-6)和C反应蛋白(CRP)水平,然后随机分为辛伐他汀治疗组和非辛伐他汀治疗组。治疗后24周检查TG、TC、CRP和IL-6。并设30例健康者作对照比较。结果①尿毒症患者TG、IL-6、CRP显著高于健康者(P<0.01);②治疗后24周,辛伐他汀治疗组TC、TG、IL-6、CRP的水平均有所下降,辛伐他汀治疗组IL-6、CRP下降的水平与治疗前及非治疗组相比,差异具有显著性,P<0.05。结论应用辛伐他汀治疗能改善尿毒症患者的微炎症状态。

Objective To observe the effects and differences of simvastain on serum lipids and inflammatory markers in patients with uremia. To investigate the treatment effects of simvastain on microinflammation state in patientswith uremia. Methods In 64 patients with uremia and 30 healthy controls the level of C-reactive protein （CRP）, Interlukin-6 （IL-6）, serum lipid level were determined ,then the patients were randomly divided into 2 groups to receive simvastatin 20mg daily or nonlipid-lowering therapy. All above parameters were assayed again after 24 weeks. Results 1. Compared with healthy, controls, the serum TG, IL-6, CRP were elevated significantly in patients with uremia. 2. After 24 weeks＇ treatment, thelevels of TG, TC, CRP and IL-6 in simvastatin group were lower than before, and the level of CRP, IL- 6 was much lower in simvastatin group than non- simvastatin group （P〈0. 05）. Conclusion Simvastatin can relieve the microinflammation state in patients with uremia.